Figure 8. Responder and seizure freedom rates at 3, 6 and 12 months and at last visit in (A) patients who transitioned from carbamazepine to eslicarbazepine acetate due to lack of efficacy (n=163) and (B) patients who transitioned from oxcarbazepine to eslicarbazepine acetate due to lack of efficacy (n=90). Response was defined as >50% seizure frequency reduction from baseline; seizure freedom was defined as no seizures since at least the prior visit (either 3 or 6 months). Reproduced with permission from Eisai